ArticleACS nano2018
Eradication of Established Tumors by Chemically Self-Assembled Nanoring Labeled T Cells.
Article in ACS nano, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- T-cell Receptor (TCR) Targeting with Multivalent T-cell Engagers.bioRxiv : the preprint server for biology · 2026Article
- Entropy-driven signal amplification integrated with machine learning in multiplex lateral flow immunoassay for sensitive Point-of-Care colon cancer diagnosis.Journal of nanobiotechnology · 2025Article
- Engineering protein prenylation: an emerging tool for selective protein modification.Biochemical Society transactions · 2025Review
- Targeted Drug Delivery by MMAE Farnesyl-Bioconjugated Multivalent Chemically Self-Assembled Nanorings Induces Potent Receptor-Dependent Immunogenic Cell Death.Bioconjugate chemistry · 2024Article
- Multivalent Fluorinated Nanorings for On-CellBiomacromolecules · 2024Article
- Nanotechnology-Aided Advancement in Combating the Cancer Metastasis.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Eradication of Heterogeneous Tumors by T Cells Targeted with Combination Bispecific Chemically Self-assembled Nanorings.Molecular cancer therapeutics · 2023Article
- Multivalent, Bispecific αB7-H3-αCD3 Chemically Self-Assembled Nanorings Direct Potent T Cell Responses against Medulloblastoma.ACS nano · 2022Article
- Nanotechnology-aided advancement in the combating of cancer metastasis.Cancer metastasis reviews · 2022Review
- Switchable assembly and function of antibody complexes in vivo using a small molecule.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Protein Assembly by Design.Chemical reviews · 2021Review
- Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma.International journal of molecular sciences · 2021Review
- Advanced biomaterials for cancer immunotherapy.Acta pharmacologica Sinica · 2020Review
- A supramolecular hydrophobic guest transport system based on a biological macrocycle.RSC advances · 2019Article
- Clickable Methyltetrazine-Indocarbocyanine Lipids: A Multicolor Tool Kit for Efficient Modifications of Cell Membranes.Bioconjugate chemistry · 2019Article
- Multivalent Ligand Binding to Cell Membrane Antigens: Defining the Interplay of Affinity, Valency, and Expression Density.Journal of the American Chemical Society · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Our laboratory has developed chemically self-assembled nanorings (CSANs) as prosthetic antigen receptors (PARs) for the nongenetic modification of T cell surfaces. PARs have been successfully employed in vitro to activate T cells for the selective killing of leukemia cells. However, PAR efficacy has yet to be evaluated in vivo or against solid tumors. Therefore, we developed bispecific PARs that selectively target the human CD3 receptor and human epithelial cell adhesion molecule (EpCAM), which is overexpressed on multiple carcinomas and cancer stem cells. The αEpCAM/αCD3 PARs were found to stably bind T cells for >4 days, and treating EpCAM
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.